Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Expanded harm reduction provision achieves impressive reductions in HCV incidence among PWID in Scotland

Implementation of comprehensive harm reduction policies has achieved impressive reductions in incidence of hepatitis C virus (HCV) infections among people who inject drugs (PWID) in Scotland, research publish

Published
20 hours ago
By
Michael Carter
Britain Has No Problem Paying for Expensive Hepatitis C Drugs

The U.K.’s decision to recommend Sovaldi was far from a sure thing. But once the National Institute for Health and Care Excellence was convinced that Sovaldi is cost-effective, the decision to pay for it is simple, because one entity pays for all the medical care in the U.K. If treating a patient with costly drugs now prevents a more expensive liver transplant in 15 years, that savings accrues to the National Health Service—and ultimately to British taxpayers.

Published
19 August 2014
From
Businessweek
PegLambda discontinued by BMS

We have concluded that given the very promising developments in HCV in terms of emerging all-oral therapeutic options, Lambda would no longer fulfill the unmet need that we had envisioned upon initiation of the clinical trials.

Published
18 August 2014
From
EATG
Emergent HCV epidemic among young, non-urban people who inject drugs in the United States

Incidence of acute hepatitis C virus (HCV) infection increased significantly among young, non-urban people who inject drugs in the United States between 2006 and 2012, investigators report in

Published
18 August 2014
By
Michael Carter
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.

Published
18 August 2014
From
Achillion press release
NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people with chronic hepatitis C. The positive recommendation follows receipt of additional information about the drug’s cost effectiveness from the manufacturer.

Published
15 August 2014
From
NICE
UK cost body backs pricey Gilead hepatitis pill for some patients

Carole Longson, director of the NICE Centre for Health Technology Evaluation, said on Friday it was now provisionally recommending Sovaldi, also known as sofosbuvir, as a cost-effective treatment for some people with chronic hepatitis C.

Published
15 August 2014
From
Reuters
OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers

Sovaldi, approved by the Food and Drug Administration (FDA) last year for the treatment of chronic hepatitis C (HCV), has a success rate better than 90 percent, and is ideal for use in opioid treatment programs (OTPs), yet payers are balking at covering it for patients who have a history of a substance use disorder (SUD), ADAW has learned.

Published
14 August 2014
From
Alcohol & Drug Abuse Weekly
Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October

Vertex Pharmaceuticals has notified health care providers that it will stop selling its first blockbuster drug, Incivek, in about two months.

Published
13 August 2014
From
Boston Business Journal (blog)
Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Share Tools Comment Print Contact Author Reprint Indian drugmakers have a shot at bringing Gilead Sciences' ($GILD) hot new hepatitis C drug to their country. The California-based company is in talks with "a handful" of Indian pharmas to take Sovaldi (sofosbuvir) to that country and other developing nations at a fraction of the U.S. price.

Published
11 August 2014
From
Fierce Pharma
← First12345...101Next →

Filter by country